高级别胶质瘤血脑屏障通透性异质性机会窗研究
本研究在高级别脑肿瘤患者术中给药,采集血浆与影像配对的肿瘤样本,用LC-MS/MS测定左乙拉西坦与头孢唑林浓度。结果显示两种药物的肿瘤/血浆浓度比在瘤内及瘤间差异显著,且强化与非强化区差异明显,提示临床MRI不能完全预测药物递送。
要点
- 左乙拉西坦瘤内渗透优于头孢唑林,但两者均存在显著瘤内异质性。
- 对比增强区与非增强区的药物浓度比差异显著,MRI预测药物递送有限。
- 术中微透析与群体药代动力学分析验证了上述异质性结果。
核心结论
- 高级别脑肿瘤内左乙拉西坦与头孢唑林递送存在显著瘤间及瘤内异质性,临床MRI不一定能预测该异质性,可能反映肿瘤所致灌注与血脑屏障完整性改变。
研究设计与样本
- 机会窗研究,42例手术病例,采集肿瘤样本125份、血浆样本261份,术前给予头孢唑林与左乙拉西坦,LC-MS/MS测药,部分患者行术中微透析。
主要发现
- 头孢唑林肿瘤/血浆比边际均值0.15(95%CI 0.11-0.19),低于左乙拉西坦0.70(95%CI 0.64-0.75),P<.001。
- 对比增强区与非增强区头孢唑林比值相差4.4倍(0.27,95%CI 0.20-0.35 vs 0.06,95%CI 0.04-0.08,P<.001)。
- 左乙拉西坦强化区与非强化区比值相差1.4倍(0.88,95%CI 0.78-0.97 vs 0.61,95%CI 0.55-0.66,P<.001)。
临床怎么用
- 提示仅凭临床MRI对比增强判断药物递送可能不足,中枢药物选择与剂量需考虑瘤内异质性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Disruption of the blood-brain barrier (BBB) in high-grade brain tumors is characterized by contrast accumulation on diagnostic imaging. This window of opportunity study correlates contrast imaging features with the tumor distribution of BBB-permeable (levetiracetam) and -impermeable (cefazolin) drugs. METHODS: Patients with a clinical diagnosis of a high-grade brain tumor underwent MRI for surgical planning. Cefazolin and levetiracetam were administered prior to skin incision, and serial plasma and image-registered tumor samples were collected during the operation. Drug levels were measured by LC-MS/MS, tissue drug levels were corrected for residual blood, and tumor-to-plasma concentration ratios were calculated. Intraoperative microdialysis was performed in a subset of patients to measure the same two drugs. RESULTS: Tumor (n = 125) and plasma (n = 261) samples were available for analysis from 42 operative cases. Across all samples, the tumor-to-plasma ratio was significantly lower for cefazolin (marginal mean [MM]: 0.15, 95% CI: 0.11-0.19) as compared to levetiracetam (MM: 0.70, 95% CI: 0.64-0.75; P < .001). When compared between contrast-enhancing and non-enhancing regions, tumor-to-plasma ratios for cefazolin varied by 4.4-fold (0.27, 95% CI: 0.20-0.35 vs. 0.06, 95% CI: 0.04-0.08, respectively; P < .001), and varied for levetiracetam by 1.4-fold (0.88, 95% CI: 0.78-0.97 vs. 0.61, 95% CI: 0.55-0.66, respectively; P < .001). These results were confirmed with the intra-operative microdialysis and a population pharmacokinetic analysis. CONCLUSIONS: This study demonstrates significant inter- and intra-tumoral heterogeneity in drug delivery for both levetiracetam and cefazolin within high-grade brain tumors that is not necessarily predicted by clinical MR imaging and may reflect tumor-induced changes in both perfusion and BBB integrity.
引用
- Oh JH, Reed SK, Riviere-Cazaux C, et al. Window of opportunity evaluation of blood-brain barrier permeability heterogeneity within and across high-grade glioma patients. Neuro Oncol. 2026. PMID: 40916832. doi:10.1093/neuonc/noaf204
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。